. Author manuscript; available in PMC: 2014 Jul 25.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Apr 4;20(7):979–985. doi: 10.1016/j.bbmt.2014.03.016

Table 7.

Phase II GVHD Prevention Trials with Tacrolimus and Mycophenolate Mofetil

Study	aGVHD Prophylaxis, n	Preparative Regimen	Graft Type	Graft Source	HLA Match	aGVHD III–IV	cGVHD	NRM^*	Median Follow-up
Nieto 2006	32	Flu/TBI 200	PBSC	SD	6/6	3%	41%^†	15%	19 mo
Sabry 2009	131	Flu/Cy	PBSC	SD	6/6	.2%^‡,^§	76%^†	15%	32 mo
Zohren 2010	50	Flu/TBI 200	PBSC	UD	10/10^‖	16%	61%	26%	37 mo

GVHD indicates graft-versus-host disease; Flu, fludarabine; TBI, total body irradiation; Cy, cyclophosphamide; PBSC, peripheral blood stem cells; SD, sibling donor; UD, unrelated donor; NRM, nonrelapse mortality.

At the median follow up.

^†

Extensive cGVHD.

^‡

Additional 12% developed overlap syndrome with no grade severity mentioned.

^§

Estimated from the curve or from the tables.

^‖

Six patients had a donor with one antigen mismatch, while one had a donor with 2 antigen mismatches.